APOA1 and myeloid sarcoma: Indeed, clinical observations indicate that individuals with progressive forms of MS exhibit significantly lower plasma ApoA-I levels compared to those with relapsing-remitting MS (RRMS) and healthy controls [128], pointing to a potential protective role of ApoA-I in disease stabilization and progression.